StockData
Alterity Therapeutics Ltd logo

Alterity Therapeutics Ltd (ATHE) shareholders

ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 28, 2026Score 5/30
$1.96+0.00 (0.00%)

Close on Nov 16, 2026Market cap $35.53MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0M
Shares held, 13F filers
Institutional holders
22
7 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $23.81K

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ATHEValueChange% of portfolio
Twin Lakes Capital Management, LLC139,258–$747.82K–0.29%
Morgan Stanley63,065–$338.66K+4,6830.00%
Greenleaf Trust62,000–$332.94K+30,0000.00%
HB Wealth Management, LLC58,460–$313.93K–0.00%
Citadel Advisors LLC37,597–$201.90K+17,5200.00%
Hrt Financial LP17,292–$92.00KNew0.00%
Bnp Paribas Arbitrage, Snc10,239–$54.98K+3,4300.00%
GAMMA Investing LLC2,309–$12.40K+4530.00%
Rhumbline Advisers2,009–$10.79K+390.00%
Acadian Asset Management LLC1,863–$10.00K–0.00%
Providence Capital Advisors, LLC200–$1.07KNew0.00%
Integrated Wealth Concepts LLC73–$392New0.00%
Osaic Holdings, Inc.68–$362–0.00%
Ronald Blue Trust, Inc.40–$215–0.00%
Farther Finance Advisors, LLC39–$205+170.00%
CoreCap Advisors, LLC21–$113–0.00%
Steward Partners Investment Advisory, LLC6–$32–0.00%
UBS Group AG5–$27New0.00%
Danske Bank A/S1–$5–0.00%
Cranbrook Wealth Management, LLC1–$6New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 2026220M7 / 70 / 00M0M
Q1 2026150M0 / 25 / 20M0M
Q4 2025180M4 / 15 / 20M0M
Q3 2025160M6 / 42 / 10M0M
Q2 2025110M2 / 11 / 30M0M
Q1 2025120M2 / 41 / 20M0M
Q4 2024130M3 / 22 / 30M0M
Q3 2024130M4 / 12 / 10M0M
Q2 2024100M2 / 01 / 20M0M
Q1 2024100M4 / 10 / 20M0M
Q4 202390M3 / 10 / 10M0M
Q3 202370M1 / 01 / 10M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

2 funds held ATHE in Q1 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ATHEValue% of fundAs of
Fidelity Nasdaq Composite Index Fund1,155–$4.76K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
David Allen StamlerChief Executive Officer, Director11,827,570Sep 8, 2026
Niven Abby Sarah MacnishChief Financial Officer454,545Apr 9, 2026
Peter Ashley MarksDirector191,340Sep 8, 2026
Lawrence Bernard GozlanDirector4,545,455Jun 23, 2026
Julian Michael BabarczyDirector–Jun 23, 2026
Ann Michelle CunninghamDirector–Apr 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Peter Ashley Marks
Director
Aug 31, 2026Buy+47,620$0.50$23.81K191,340

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-36.1%
From 0M shares
Short volume, 20 days
55.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alterity Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,000 shares on Oct 2, 2026 over the last 90 days.

See a number that looks wrong?